Investigational anti-hyperglycemic agents: The future of type 2 diabetes therapy?

Endocrine

Volumn 44, Issue 1, 2013, Pages 47-58

  Majumdar, Sachin K ^a   Inzucchi, Silvio E ^b  

^a BRIDGEPORT HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

11 HSD1 inhibitors; Free fatty acid receptor agonists; Glucokinase activators; Incretin based therapies; Investigational diabetes agents; New diabetes drugs; SGLT2 inhibitors; Type 2 diabetes

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBIGLUTIDE; ALEGLITAZAR; ANTIDIABETIC AGENT; BALAGLITAZONE; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DUAL PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; DULAGLUTIDE; EXENDIN 4; FREE FATTY ACID RECEPTOR AGONIST; FRUCTOSE BISPHOSPHATASE INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON RECEPTOR ANTAGONIST; GLUCOKINASE ACTIVATOR; INCRETIN; INSULIN; LIXISENATIDE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; RANOLAZINE; SALICYLIC ACID DERIVATIVE; SODIUM COUPLED GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVERSE DRUG REACTION; AGE; ALBUMINURIA; BONE DISEASE; COMORBIDITY; DEHYDRATION; DIABETOGENESIS; DISEASE COURSE; DIZZINESS; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG USE; EDEMA; EXPERIMENTAL THERAPY; FATTY LIVER; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOLYSIS; PANDEMIC; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOCIAL STATUS; UROGENITAL TRACT INFECTION; WEIGHT GAIN;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUGS, INVESTIGATIONAL; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GLUCAGON; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84881161401     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-9884-3     Document Type: Review

References (136)

1. http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed 26 December 2012
2. http://www.cdc.gov/chronicdisease/resources/publications/AAG/ddt.htm. Accessed 26 December 2012
3. G. Danaei, M.M. Finucane, Y. Lu, G.M. Singh, M.J. Cowan, C.J. Paciorek, J.K. Lin, F. Farzadfar, Y.H. Khang, G.A. Stevens, M. Rao, M.K. Ali, L.M. Riley, C.A. Robinson, M. Ezzati, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (blood glucose), National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378(9785), 31-40 (2011)
4. M. Stumvoll, B.J. Goldstein, T.W. Van Haeften, Type 2 diabetes: principals of pathogenesis and therapy. Lancet 365, 1333-1346 (2005)
5. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A.L. Peters, A. Tsapas, R. Wender, D.R. Matthews, Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care 35, 1364-1379 (2012)
6. R.C. Turner, C.A. Cull, V. Frighi, R.R. Holman, Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK prospective diabetes study (UKPDS) Group. JAMA 281, 2005-2012 (1999)
7. D.J. Graham, C.R. Drinkard, D. Shatin, Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am. J. Gastroenterol. 98, 175-179 (2003)
8. S.E. Nissen, K. Wolski, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007)
9. J.D. Lewis, A. Ferrara, T. Peng, M. Hedderson, W.B. Bilker, C.P. Quesenberry Jr, D.J. Vaughn, L. Nessel, J. Selby, B.L. Strom, Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34, 916-922 (2011)
10. T. Mancini, G. Mazziotti, M. Doga, R. Carpinteri, N. Simetovic, P.P. Vescovi, A. Giustina, Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 45, 784-788 (2009)
11. R.A. DeFronzo, From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58, 773-795 (2009)
12. V.T. Samuel, K.F. Peterson, G.I. Shulman, Lipid-induced insulin resistance: unraveling the mechanism. Lancet 375(9733), 2267-2277 (2010)
13. N. Ouchi, J.L. Parker, J.J. Lugus, K. Walsh, Adipokines in inflammation and metabolic disease. Nat. Rev. 11, 85-97 (2011)
14. M. Bergman, Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine. doi: 10.1007/s12020-012-9830-9
15. M. Pardo, A. Roca-Rivada, L.M. Seoane, F.F. Casanueva, Obesidomics: contribution of adipose tissue secretome analysis to obesity research. Endocrine 41(3), 374-383 (2012)
16. A.E. Butler, J. Jansen, S. Bonner-Weir, R. Ritzel, R.A. Rizza, Betacell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 47, 358-364 (1998)
17. R. Lupi, S. Del Prato, β-cell apoptosis in type 2 diabetes: quantitative and functional consequences. Diabetes Metab. 34, S56-S64 (2008)
18. M. Marc Prentki, C.J. Nolan, Islet β-cell failure in type 2 diabetes. J. Clin. Investig. 116(7), 1802-1812 (2006)
19. T. Vilsboll, J.J. Holst, Incretins, insulin secretion and type2 diabetes mellitus. Diabetologia 47, 357-366 (2004)
20. L.L. Baggio, D.J. Drucker, Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157 (2007)
21. D.J. Drucker, M.A. Nauck, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696-1705 (2006)
22. J.J. Meier, B. Gallwitz, N. Siepmann, J.J. Holst, C.F. Deacon, W.E. Schmidt, M.A. Nauck, Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46, 798-801 (2003)
23. J. Girard, The incretins: from the concept to their use in the treatment of type2 diabetes. Part A: incretins: concept and physiological functions. Diabetes Metab. 34, 550-559 (2008)
24. D.J. Drucker, The biology of incretin hormones. Cell Metab. 3(3), 153-165 (2006)
25. R. Goke, H.C. Fehmann, T. Thomas Linn, H. Schmidt, M. Krause, J. John Eng, B. GokeI, Exendin-4 Is a high potency agonist and truncated exendin-(9-39)- amide and antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta cells. J. Biol. Chem. 268(15), 1960-19655 (1993)
26. R.A. DeFronzo, R.E. Ratner, J. Han, D.D. Kim, M.S. Fineman, A.D. Baron, Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin treated patients with type 2 diabetes. Diabetes Care 28, 1092-1100 (2005)
27. R.J. Heine, L.F. VanGaal, D. Johns, M.J. Mihm, M.H. Widel, R.G. Brodows, GWAA Study Group, Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann. Intern. Med. 143, 559-569 (2005)
28. J.B. Buse, R.R. Henry, J. Han, D.D. Kim, M.S. Fineman, A.D. Baron, Exenatide-113 Clinical Study Group, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27, 2628-2635 (2004)
29. T. Blevins, J. Pullman, J. Malloy, P. Yan, K. Taylor, C. Schulteis, M. Trautmann, L. Porter, DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J/ Clin. Endocrin. Metab. 96(5), 1301-1310 (2011)
30. http://clinicaltrials.gov/ct2/show/NCT01455896?term=ITCA+DUROS. Accessed 26 December 2012
31. ® technology delivers peptides and proteins at a consistent rate continuously for 3-12 months. J. Diabetes Sci. Technol. 2(3), 461-467 (2008)
32. C.C.L. Quianzon, M.E. Shomali, Lixisenatide - Once-daily glucagon-like peptide 1 receptor agonist in the management of type 2 diabetes. Eur. Endocrinol. 8(1), 104-109 (2012)
33. J. Rosenstock, J. Reusch, M. Bush, F. Yang, M. Stewart, Albiglutide Study Group, Albiglutide Study Group. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 32, 1880-1886 (2009)
34. http://clinicaltrials.gov/ct2/results?term=LY2189265. Accessed 26 December 2012
35. J. J. Meier, GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. doi: 10.1038/nrendo.2012.140
36. R.E. Pratley, M.S. Kipnes, P.R. Fleck, C. Wilson, Q. Mekki, Alogliptin Study 007 Group, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes. Metab. 11, 167-176 (2009)
37. B. Lee, L. Shi, D.B. Kassel, T. Asakawa, K. Takeuchi, R.J. Christopher, Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur. J. Pharmacol. 589, 306-314 (2008)
38. L. Thomas, M. Eckhardt, E. Langkopf, M. Tadayyon, F. Himmelsbach, M. Mark, (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4- methylquinazolin-quinazolin- 2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthinebased dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J. Pharmacol. Exp. Ther. 325, 175-182 (2008)
39. http://www.furiex.com/pipeline/discoverydevelopment-pipeline/syr-472/. Accessed 26 December 2012
40. M. Kirby, D.M.T. Yu, S.P. O'Connor, M.D. Gorrell, Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin. Sci. 118, 31-41 (2010)
41. B.D. Abbott, Review of the expression of peroxisome proliferator- activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development. Reprod. Toxicol. 27(3-4), 246-257 (2009)
42. S. Mandard, M. Muller, S. Kersten, Peroxisome proliferator-activated receptor α target genes. Cell. Mol. Life Sci. 61, 393-416 (2004)
43. R.K. Semple, V.K.K. Chatterjee, S.O. O'Rahilly, PPARγ and human metabolic disease. J. Clin. Investig. 116, 581-589 (2006)
44. G.D. Barish, V.A. Narker, R.M. Evans, PPARδ: a dagger in the heart of the metabolic syndrome. J. Clin. Investig. 116, 590-596 (2006)
45. S.E. Kahn, S.M. Haffner, M.A. Heise, W.H. Herman, R.R. Holman, N.P. Jones, B.G. Kravitz, J.M. Lachin, G. Viberti, for the ADOPT Study Group, Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427-2443 (2006)
46. D. Jones, Potential remains for PPAR-targeted drugs. Nat. Rev. Drug Discov. 9, 668-669 (2010)
47. K. Henriksen, I. Byrjalsen, P. Qvist, H. Beck-Nielsen, G. Hansen, B.J. Riis, H. Perrild, O.L. Svendsen, J. Gram, M.A. Karsdal, C. Christiansen, BALLET trial investigators, Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. Diabetes Metab Res Rev. 4, 392-401 (2011)
48. F.M. Gregoire, F. Zhang, H.J. Clarke, T.A. Gustafson, D.D. Sears, S. Favelyukis, J. Lenhard, D. Rentzeperis, L.E. Clemens, Y. Mu, B. Levan, MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol. Endocrinol. 23, 975-988 (2009)
49. H.W. Lee, J.B. Ahn, S.K. Kang, S.K. Ahn, D.C. Ha, Process development and scale-up of PPAR α/γ dual agonist lobeglitazone sulfate (CKD-501). Org. Process Res. Dev. 11(2), 190-199 (2007)
50. B. Lecka-Czernik, Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus. IDrugs 13(11), 793-801 (2010)
51. http://clinicaltrials.gov/ct2/show/NCT01106131. Accessed 26 December 2012
52. http://clinicaltrials.gov/ct2/show/NCT01042769. Accessed 26 December 2012
53. E. Scorletti, P.C. Calder, C.D. Byrne, Non alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 40, 332-343 (2011)
54. R. Belfort, S.A. Harrison, K. Brown, C. Darland, J. Finch, J. Hardies, B. Balas, A. Gastadelli, F. Tio, J. Pulcini, R. Berria, J.Z. Ma, S. Dwivedi, R. Havranek, C. Fincke, R. DeFronzo, G.A. Bannayan, S. Schenker, K. Cusi, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355, 2297-2307 (2006)
55. J.R. Ehrenkranz, N.G. Lewis, C.R. Kahn, J. Roth, Phlorizin: a review. Diabetes Metab. Res. Rev. 21, 31-38 (2005)
56. E.M. Wright, D.D. Loo, B.A. Hirayama, Biology of human sodium glucose transporters. Physiol. Rev. 91, 733-794 (2011)
57. +/d-glucose cotransporters SGLT1 and SGLT2. Am. J. Physiol. Cell Physiol. 300, C14-C21 (2011)
58. G.L. Bakris, V.A. Fonseca, K. Sharma, E.M. Wright, Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 75(12), 1272-1277 (2009)
59. J. Calado, K. Soto, C. Clemente, P. Correia, J. Rueff, Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria. Hum. Genet. 114, 314-316 (2004)
60. R. Santer, J. Calado, Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin. J. Am. Soc. Nephrol. 5(1), 133-141 (2010)
61. H. Rahmoune, P.W. Thompson, J.M. Ward, C.D. Smith, G. Hong, J. Brown, Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54, 3427-3434 (2005)
62. FDA BRIEFING DOCUMENT NDA 202293. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm262994.pdf. Accessed 26 December 2012
63. http://www.ukmi.nhs.uk/applications/ndo/record-view-open.asp?newDrugID= 4403. Accessed 26 December 2012
64. J.P.H. Wilding, V. Vincent, N.G. Soler, A. Pahor, J. Sugg, K. Rohwedder, S. Parikh, for the Dapagliflozin 006 Study Group, Long-term efficacy of Dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin A randomized trial. Ann. Intern. Med. 156, 405-415 (2012)
65. S.L. Anderson, J.C. Marrs, Dapagliflozin for the treatment of type 2 diabetes. Ann. Pharmacother. 46(4), 590-598 (2012)
66. M. Misra, SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. J. Pharm. Pharmacol. 1-11, Article first published online: 9 AUG 2012
67. http://www.empr.com/phase-3-trial-update-of-canagliflozin-for-type-2- diabetes/article/261803/. Accessed 26 December 2012
68. http://www.boehringer-ingelheim.com/news/news-releases/press-releases/ 2012/02-october-2012-empagliflozin.html. Accessed 26 December 2012
69. J.P. Ly, T. Onay, K. Sison, G. Sivaskandarajah, V. Sabbisetti, L. Li, J.B. Bonventre, A. Flenniken, N. Paragas, J.M. Barasch, S.L. Adamson, L. Osborne, J. Rossant, J. Schnermann, S.E. Quaggin, The Sweet Pee model for Sglt2 Mutation. J. Am. Soc. Nephrol. 22(1), 113-123 (2011)
70. B. Ahren, Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat. Rev. 8, 369-384 (2009)
71. A. Salehi, E. Flodgren, N.E. Nilsson, J. Jimenez-Feltstrom, J. Miyazaki, C. Owman, B. Olde, Free fatty acid receptor 1 (FFA 1R/GPR40) and its involvement in fatty-acid-stimulated insulin secretion. Cell Tissue Res. 322, 207-215 (2005)
72. E. Flodgren, B. Olde, S. Meidute-Abaraviciene, M.S. Winzel, B. Ahrén, A. Salehi, GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem. Biophys. Res. Commun. 354, 240-245 (2007)
73. J. Gromada, The free fatty acid receptor GPR40 generates excitement in pancreatic β-cells. Endocrinology 147, 672-673 (2008)
74. H.A. Overton, M.C.T. Fyfe, C. Reynet, GPR119, a novel G protein-c oupled receptor target for the treatment of type 2 diabetes and obesity. Br. J. Pharmacol. 153, S76-S81 (2008)
75. G. Flock, D. Holland, Y. Seino, D.J. Drucker, GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. Endocrinology 152, 374-383 (2011)
76. C.F. Burant, P. Viswanathan, J. Marcinak, C. Cao, M. Vakilynejad, B. Xie, E. Leifke, TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379, 1403-1411 (2012)
77. http://clinicaltrials.gov/ct2/results?term=TAK+875. Accessed 26 December 2012
78. S. Hardy, G. St-Onge, E. Joly, Y. Langelier, M. Prentki, Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40. J. Biol. Chem. 280, 13285-13291 (2005)
79. P. Steneberg, N. Rubins, R. Bartoov-Shifman, M.D. Walker, H. Edlund, The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impairedglucose homeostasis in mouse. Cell Metab. 1, 245-258 (2005)
80. M. Kebede, T. Alquier, M.G. Latour, M. Semache, C. Tremblay, V. Poitout, The fatty-acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 57, 2432-2437 (2008)
81. C.P. Tan, Y. Feng, Y.P. Zhou, G.J. Eiermann, A. Petrov, C. Zhou, S. Lin, G. Salituro, P. Meinke, R. Mosley, T.F. Akiyama, M. Einstein, S. Kumar, J.P. Berger, S.G. Mills, N.A. Thornberry, L. Yang, A. Howard, Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose dependent insulin secretion and reduce blood glucose in mice. Diabetes 57, 2211-2219 (2008)
82. A.L. Albiston, V.R. Obeyesekere, R.E. Smith, Z.S. Krozowski, Cloning and tissue distribution of the human 11-β-hydroxysteroid dehydrogenase type 2 enzyme. Mol. Cell. Endocrinol. 105, R11-R17 (1994)
83. P.M. Stewart, Z.S. Krozowski, 11-β-Hydroxysteroid dehydrogenase. Vitam. Horm. 57, 249-324 (1999)
84. A. Munck, P.M. Guyre, N.J. Holbrook, Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr. Rev. 5(1), 25-44 (1984)
85. G. Mazziotti, C. Gazzaruso, A. Giustina, Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol. Metab. 22(12), 499-506 (2011)
86. R. Giordano, F. Guaraldi, R. Berardelli, I. Karamouzis, V. D'Angelo, E. Marinazzo, A. Picu, E. Ghigo, E. Arvat, Glucose metabolism in patients with subclinical Cushing's syndrome. Endocrine 41(3), 415-423 (2012)
87. H. Liu, D.M. Bravata, J. Cabaccan, H. Raff, E. Ryzen, Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans. Clin. Endocrinol. 63, 642-649 (2005)
88. I. Chiodini, G. Adda, A. Scillitani, F. Coletti, V. Morelli, S. Di Lembo, P. Epaminonda, B. Masserini, P. Beck-Peccoz, E. Orsi, B. Ambrosi, M. Arosio, Cortisol secretion in patients with type 2 diabetes relationship with chronic complications. Diabetes Care 30(1), 83-88 (2007)
89. Y. Valsamakis, A. Anwar, J.W. Tomlinson, C.H.L. Shackleton, P.G. McTernan, R. Chetty, P.J. Wood, A.K. Banerjee, G. Holder, A.H. Barnett, P.M. Stewart, S. Kumar, 11-β-Hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 89, 4755-4761 (2004)
90. Y. Kotelevtsev, M.C. Holmes, A. Burchell, P.M. Houston, D. Schmoll, P. Jamieson, R. Best, R. Brown, C.R. Edwards, J.R. Seckl, J.J. Mullins, 11-β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. USA. 94(26), 14924-14929 (1997)
91. K.A. Hughes, S.P. Webster, B.P. Walker, 11-β-Hydroxysteroid dehydrogenase type 1 (11 b -HSD1) inhibitors in Type 2 diabetes mellitus and obesity. Expert Opin. Investig. Drugs 17(4), 481-496 (2008)
92. J. Rosenstock, S. Banarer, V.A. Fonseca, S.E. Inzucchi, W. Sun, W. Yao, G. Hollis, R. Flores, R. Levy, W.V. Williams, J.R. Seckl, R. Huber, INCB13739-202 Principal Investigators, The 11-β-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33(7), 1516-1522 (2010)
93. M. Wang, Inhibitors of 11-β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. Handb. Exp. Pharmacol. 203, 127-146 (2011)
94. T.C. Sandeep, J.L. Yau, A.M. MacLullich, J. Noble, I.J. Deary, B.R. Walker, J.R. Seckl, 11-β-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc. Natl. Acad. Sci. USA 101(17), 6734-6739 (2004)
95. B.M. Abdallah, H. Beck-Nielsen, M. Gaster, Increased expression of 11-β-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes. Eur. J. Clin. Investig. 35, 627-634 (2005)
96. J.W. Tomlinson, E.A. Walker, I.J. Bujalska, N. Draper, G.G. Lavery, M.S. Cooper, M. Hewison, P.M. Stewart, 11-β-Hydroxysteroid dehydrogenase type 1: a tissuespecific regulator of glucocorticoid response. Endocr. Rev. 25(5), 831-866 (2004)
97. C. Postic, M. Shiota, M.A. Magnuson, Cell-specific roles of glucokinase in glucose homeostasis. Recent Prog. Horm. Res. 56, 195-217 (2001)
98. T.L. Jetton, Y. Liang, C.C. Pettepher, E.C. Zimmerman, F.G. Cox, K. Horvath, F.M. Matschinsky, M.A. Magnuson, Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut. J. Biol. Chem. 269, 3641-3654 (1994)
99. R.L. Sorenson, L.E. Stout, T.C. Brelje, T.L. Jetton, F.M. Matschinsky, Immunohistochemical evidence for the presence of glucokinase in the gonadotropes and thyrotropes of the anterior pituitary gland of rat and monkey. J. Histochem. Cytochem. 55(6), 555-566 (2007)
100. A.L. Gloyn, K. Noordam, M.A. Willemsen, S. Ellard, W.W. Lam, I.W. Campbell, P. Midgley, C. Shiota, C. Buettger, M.A. Magnuson, F.M. Matschinsky, A.T. Hattersley, Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes 52(9), 2433-2440 (2003)
101. A.L. Gloyn, Glucokinase (GCK) mutations in hyper- and hypo-glycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Human Mutat. 22(5), 353-362 (2003)
102. F.M. Matschinsky, B. Zelent, N. Doliba, C. Li, J.M. Vanderkooi, A. Naji, R. Sarabu, J. Grimsby, Glucokinase activators for diabetes therapy: May 2010 status report. Diabetes Care 34(Suppl 2), S236-S243 (2011)
103. F.M. Matschinsky, Assessing the potential for glucokinase activators in diabetes therapy. Nat. Rev. 8, 399-415 (2009)
104. R.C. Bonadonna, T. Heise, C. Arbet-Engels, C. Kapitza, A. Avogaro, J. Grimsby, J. Zhi, J.F. Grippo, R. Balena, Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus. A mechanistic study. J. Clin. Endocrinol. Metab. 95, 5028-5036 (2010)
105. M. Sjöstrand, H. Ericsson, M. Hartford, E. Norjavaara, J. W. Eriksson, Pharmacodynamic effects of the oral glucokinase activator AZD6370 after single doses in healthy volunteers assessed with euglycaemic clamp. Diabetes Obes. Metab. 2012 Sep 9. doi: 10.1111/j.1463-1326.2012.01672.x. [Epub ahead of print]
106. E. Norjavaara, H. Ericsson, F. Sjöberg, M. Leonsson-Zachrisson, M. Sjöstrand, L.A. Morrow, M. Hompesch, Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males. Clin. Endocrinol. Metab. 9, 3319-3325 (2012)
107. R.T. Williamson, On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br. Med. J. 1, 760-762 (1901)
108. S.E. Shoelson, J. Lee, A.B. Goldfine, Inflammation and insulin resistance. J. Clin. Investig. 116(7), 1793-1801 (2006)
109. A.B. Goldfine, V. Fonseca, K.A. Jablonski, L. Pyle, M.A. Staten, S.E. Shoelson, For the TINSAL-T2D.: the effects of salsalate on glycemic control in patients with type 2 diabetes. A randomized trial. Ann. Intern. Med. 152, 346-357 (2010)
110. S.L. Hale, J.C. Shryock, L. Belardinelli, M. Sweeney, R.A. Kloner, Late sodium current inhibition as a new cardioprotective approach. J. Mol. Cell. Cardiol. 44, 954-967 (2008)
111. A.D. Timmis, B.R. Chaitman, M. Crager, Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur. Heart J. 27, 42-48 (2006)
112. J. Ning, W. Zhen, Fu, J. Jiang, D. Liu, L. Belardinelli, A.K. Dhalla, Ranolazine increases β-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice. J. Pharm. Exp. Ther. 337(1), 50-58 (2011)
113. A. K. Dhalla, D. Liu, M. Santikul, L. Belardinelli, L., Ranolazine increases glucose stimulated insulin secretion in rats. J. Am. Coll. Cardiol. 51 (suppl), A321 Abstract (2008)
114. J.W. Chisholm, A.B. Goldfine, A.K. Dhalla, E. Braunwald, D.A. Morrow, E. Karwatowska-Prokopczuk, L. Belardinelli, Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care 33(6), 1163-1168 (2010)
115. D.A. Morrow, B.M. Scirica, B.R. Chaitman, D.K. McGuire, S.A. Murphy, E. Karwatowska-Prokopczuk, C.H. McCabe, E. Braunwald, for the MERLIN-TIMI 36 Investigators, Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 119, 2032-2039 (2009)
116. A. Rudnitskaya, D.A. Borkin, K. Huynh, B. Torok, K. Stieglitz, Rational design, synthesis, and potency of N-substituted indoles, pyrroles, and triarylpyrazoles as potential fructose 1,6-bisphosphatase inhibitors. Chem. Med. Chem. 5, 384-389 (2010)
117. S. Visinoni, B.C. Fam, A. Blair, C. Rantzau, B.J. Lamont, R. Bouwman, M.J. Watt, J. Proietto, J.M. Favaloro, S. Andrikopoulos, Increased glucose production in mice overexpressing human fructose-1,6-bisphosphatase in the liver. Am. J. Physiol. Endocrinol. Metab. 295, E1132-E1141 (2008)
118. A.S. Pagliari, I.E. Karl, J.P. Keating, B. Brown, D.M. Kipnis, Hepatic fructose-1,6-diphosphatase deficiency: a cause of lactic acidosis and hypoglycemia in infancy. J. Clin. Investig. 51(8), 2115-2123 (1972)
119. http://professional.diabetes.org/Abstracts-Display.aspx?TYP=1&CID= 74817. Accessed 26 December 2012
120. Z.Y. Zhang, S.Y. Lee, PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Expert Opin. Investig. Drugs 12(2), 223-233 (2003)
121. L. Lessard, M. Stuible, M.L. Tremblay, The two faces of PTP1B in cancer. Biochim. Biophys. Acta 1804(3), 613-619 (2010). Epub 2009 Sep 24
122. L. Seokjoon, W. Qian, Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B. Med. Res. Rev. 27, 553-573 (2007)
123. C. Angelini, C. Trevisan, G. Isaya, G. Pegolo, L. Vergani, Clinical varieties of carnitine and carnitine palmitoyltransferase deficiency. Clin. Biochem. 21(1), 1-7 (1987)
124. http://ghr.nlm.nih.gov/condition/carnitine-palmitoyltransferase-i- deficiency. Accessed 26 December 2012
125. N.F. Brown, D.J. McGary, The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem. 244, 1-14 (1997)
126. R. Conti, E. Mannucci, P. Pessotto, E. Tassoni, P. Carminati, F. Giannessi, A. Arduini, Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis. Diabetes 60(2), 644-651 (2011)
127. S.J. Wakil, L.A. Abu-Elheiga, Fatty acid metabolism: target for metabolic syndrome. J. Lipid Res. 50, S138-S143 (2009)
128. D.B. Savage, C.S. Choi, V.T. Samuel, Z. Liu, D. Zhang, A. Wang, X. Zhang, G.W. Cline, X.X. Yu, J.G. Geisler, S. Bhanot, B.P. Monia, G.I. Shulman, Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J. Clin. Investig. 116(3), 817-824 (2006)
129. L. Abu-Elheiga, M.M. Matzuk, K.A.H. Abo-Hashema, S.J. Wakil, Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 291, 2613-2616 (2001)
130. J.W. Corbett, J.H. Harwood Jr, Inhibitors of mammalian acetyl-CoA carboxylase. Recent Pat. Cardiovasc. Drug Discov. 2(3), 162-180 (2007)
131. S. Ali, D.J. Drucker, Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 296, E415-E421 (2009)
132. K.F. Petersen, J.T. Sullivan, Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44(11), 2018-2024 (2001)
133. G. Jiang, B. Zhang, Glucagon and regulation of glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 284, E671-E678 (2003)
134. F. De Ceuninck, C. Karger, C. Llic, A. Caliez, J.O. Rolin, T. Umbdenstock, C. Vinson, M. Combettes, B. De Fanti, E. Harley, M. Sadlo, A.L. Lefevre, O. Broux, M. Wierzbicki, J.M. Fourquez, F. Perron-Sierra, A. Kotschy, A. Ktorza, Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br. J. Pharmacol. 168(2), 339-353 (2013). Article first published online: 20 DEC 2012
135. A. Grefhorst, J. Hoekstra, T.G. Derks, D.M. Ouwens, J.F. Baller, R. Havinga, L.M. Havekes, J.A. Romijn, F. Kuipers, Acute hepatic steatosis in mice by blocking β-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production. Am. J. Gastrointest. Liver Physiol. 289(3), G592-G598 (2005)
136. N.F. Brown, R.S. Mullur, I. Subramanian, V. Esser, M.J. Bennett, J. Saudubray, A.S. Feigenbaum, J.A. Kobari, P.M. Macleod, D.J. McGarry, J.C. Cohen, Molecular characterization of L-CPT 1 deficiency in six patients: insights into function of the native enzyme. J. Lipid Res. 42, 1134-1142 (2001)